Key Highlights

• Shares closed at $5.87, down more than 16% on June 24, with no identifiable company-specific trigger.

• SciSparc has a market capitalization under $15 million and minimal institutional following, amplifying single-session volatility.

• The company is developing cannabinoid and other treatments for ADHD and Tourette syndrome.

• Outsized percentage swings in both directions are a recurring feature of the stock's trading pattern.

SciSparc Ltd. (NASDAQ:SPRC) closed at $5.87 on June 24, a decline of more than 16% with no company-specific announcement identified as the catalyst.

The company is a clinical-stage biopharmaceutical firm developing cannabinoid-based and other therapies for neurological conditions including attention deficit hyperactivity disorder and Tourette syndrome. Its pipeline remains in early clinical stages with limited near-term binary readouts flagged.

SciSparc carries a market capitalization below $15 million and has minimal institutional ownership. These structural characteristics, a thin float and sparse institutional following, make outsized single-session percentage moves a routine feature of the stock's behavior in both directions.

The June 24 decline is consistent with broad healthcare sector de-risking rather than any pipeline-specific development. No regulatory, clinical, or corporate action was identified on the date.